LinkedIn Profile

Access Dimension Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:dmtx 5052533 Aug 30th, 2021 12:00AM Dimension Therapeutics 3.0K 5.00 Open Biotechnology Aug 30th, 2021 09:51AM Aug 30th, 2021 09:51AM Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In June 2014, Dimension announced a collaboration and license agreement with Bayer HealthCare, a worldwide leader in hemophilia, for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Dimension is responsible for all pre-clinical development activities and the Phase 1/2a clinical trial, with funding from Bayer. Bayer will conduct the confirmatory Phase 3 trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Through its license and collaboration with REGENX, Dimension acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Open Open 840 Memorial Drive Cambridge MA US Dimension Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:dmtx 5052533 Aug 29th, 2021 12:00AM Dimension Therapeutics 3.0K 5.00 Open Biotechnology Aug 29th, 2021 03:51PM Aug 29th, 2021 03:51PM Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In June 2014, Dimension announced a collaboration and license agreement with Bayer HealthCare, a worldwide leader in hemophilia, for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Dimension is responsible for all pre-clinical development activities and the Phase 1/2a clinical trial, with funding from Bayer. Bayer will conduct the confirmatory Phase 3 trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Through its license and collaboration with REGENX, Dimension acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Open Open 840 Memorial Drive Cambridge MA US Dimension Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:dmtx 5052533 Aug 28th, 2021 12:00AM Dimension Therapeutics 3.0K 5.00 Open Biotechnology Aug 28th, 2021 02:21PM Aug 28th, 2021 02:21PM Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In June 2014, Dimension announced a collaboration and license agreement with Bayer HealthCare, a worldwide leader in hemophilia, for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Dimension is responsible for all pre-clinical development activities and the Phase 1/2a clinical trial, with funding from Bayer. Bayer will conduct the confirmatory Phase 3 trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Through its license and collaboration with REGENX, Dimension acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Open Open 840 Memorial Drive Cambridge MA US Dimension Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:dmtx 5052533 Aug 27th, 2021 12:00AM Dimension Therapeutics 3.0K 5.00 Open Biotechnology Aug 27th, 2021 10:07AM Aug 27th, 2021 10:07AM Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In June 2014, Dimension announced a collaboration and license agreement with Bayer HealthCare, a worldwide leader in hemophilia, for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Dimension is responsible for all pre-clinical development activities and the Phase 1/2a clinical trial, with funding from Bayer. Bayer will conduct the confirmatory Phase 3 trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Through its license and collaboration with REGENX, Dimension acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Open Open 840 Memorial Drive Cambridge MA US Dimension Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:dmtx 5052533 Aug 26th, 2021 12:00AM Dimension Therapeutics 3.0K 5.00 Open Biotechnology Aug 26th, 2021 08:44AM Aug 26th, 2021 08:44AM Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In June 2014, Dimension announced a collaboration and license agreement with Bayer HealthCare, a worldwide leader in hemophilia, for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Dimension is responsible for all pre-clinical development activities and the Phase 1/2a clinical trial, with funding from Bayer. Bayer will conduct the confirmatory Phase 3 trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Through its license and collaboration with REGENX, Dimension acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Open Open 840 Memorial Drive Cambridge MA US Dimension Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:dmtx 5052533 Aug 25th, 2021 12:00AM Dimension Therapeutics 3.0K 5.00 Open Biotechnology Aug 25th, 2021 08:43AM Aug 25th, 2021 08:43AM Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In June 2014, Dimension announced a collaboration and license agreement with Bayer HealthCare, a worldwide leader in hemophilia, for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Dimension is responsible for all pre-clinical development activities and the Phase 1/2a clinical trial, with funding from Bayer. Bayer will conduct the confirmatory Phase 3 trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Through its license and collaboration with REGENX, Dimension acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Open Open 840 Memorial Drive Cambridge MA US Dimension Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:dmtx 5052533 Aug 24th, 2021 12:00AM Dimension Therapeutics 3.0K 5.00 Open Biotechnology Aug 24th, 2021 08:06AM Aug 24th, 2021 08:06AM Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In June 2014, Dimension announced a collaboration and license agreement with Bayer HealthCare, a worldwide leader in hemophilia, for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Dimension is responsible for all pre-clinical development activities and the Phase 1/2a clinical trial, with funding from Bayer. Bayer will conduct the confirmatory Phase 3 trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Through its license and collaboration with REGENX, Dimension acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Open Open 840 Memorial Drive Cambridge MA US Dimension Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:dmtx 5052533 Aug 23rd, 2021 12:00AM Dimension Therapeutics 3.0K 5.00 Open Biotechnology Aug 23rd, 2021 10:56AM Aug 23rd, 2021 10:56AM Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In June 2014, Dimension announced a collaboration and license agreement with Bayer HealthCare, a worldwide leader in hemophilia, for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Dimension is responsible for all pre-clinical development activities and the Phase 1/2a clinical trial, with funding from Bayer. Bayer will conduct the confirmatory Phase 3 trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Through its license and collaboration with REGENX, Dimension acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Open Open 840 Memorial Drive Cambridge MA US Dimension Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:dmtx 5052533 Aug 22nd, 2021 12:00AM Dimension Therapeutics 3.0K 5.00 Open Biotechnology Aug 22nd, 2021 11:45AM Aug 22nd, 2021 11:45AM Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In June 2014, Dimension announced a collaboration and license agreement with Bayer HealthCare, a worldwide leader in hemophilia, for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Dimension is responsible for all pre-clinical development activities and the Phase 1/2a clinical trial, with funding from Bayer. Bayer will conduct the confirmatory Phase 3 trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Through its license and collaboration with REGENX, Dimension acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Open Open 840 Memorial Drive Cambridge MA US Dimension Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:dmtx 5052533 Aug 21st, 2021 12:00AM Dimension Therapeutics 3.0K 5.00 Open Biotechnology Aug 20th, 2021 10:26PM Aug 21st, 2021 03:24PM Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In June 2014, Dimension announced a collaboration and license agreement with Bayer HealthCare, a worldwide leader in hemophilia, for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Dimension is responsible for all pre-clinical development activities and the Phase 1/2a clinical trial, with funding from Bayer. Bayer will conduct the confirmatory Phase 3 trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Through its license and collaboration with REGENX, Dimension acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Open Open 840 Memorial Drive Cambridge MA US Dimension Therapeutics Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.